I wonder why Aethlon Medical, Inc. (AEMD) is going downhill in the premarket?

Will we continue down this path, and if so, why? I suspect the NASDAQ-listed shares of Centennial Resource Development, Inc. might provide a clue to the answer. As of today, there have been no new developments with regards to the company, but it continues to fall consistently as Aethlon Medical, Inc. (Nasdaq: AEMD) shares drowned 6.73% to 2.08 in the premarket session.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now. 

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.
Sponsored

And all this shows me is that investors are all quite shaken up by Aethlon Medical, Inc. (Nasdaq: AEMD) news on December 16, 2020, that the first patient was treated in the Company’s first clinical Early Feasibility Trial testing HEMOPURIFIER in patients with chronic and/or metastatic head and neck squamous cell carcinoma.

Read More

The study is enrolling patients at UPMC Hillman Cancer Center in Pittsburgh, PA. Hemopurifier Plus Pembrolizumab in Head and Neck Cancer. I wondered whether all the anxiety was overblown.

Most Popular

Related posts